NasdaqCM - Nasdaq Real Time Price USD

Compugen Ltd. (CGEN)

1.2600

-0.0300

(-2.33%)

At close: May 9 at 4:00:00 PM EDT

1.2900

+0.03

+(2.38%)

After hours: May 9 at 5:35:41 PM EDT

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

PR Newswire 6 days ago

CGEN
-2.33%
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025:

PR Newswire last month

CGEN
-2.33%
Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Compugen Ltd. (NASDAQ:CGEN) stands against other penny stocks with the biggest upside potential. Penny stocks trade below $5 and attract investors looking for high returns with a […]

Insider Monkey last month

CGEN
-2.33%
Calculating The Intrinsic Value Of Compugen Ltd. (NASDAQ:CGEN)

Key Insights The projected fair value for Compugen is US$1.92 based on 2 Stage Free Cash Flow to Equity Current share...

Simply Wall St. 2 months ago

CGEN
-2.33%
Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Compugen Ltd (CGEN) showcases promising developments in oncology treatments while navigating a decrease in annual revenue and a net loss for 2024.

GuruFocus.com 2 months ago

CGEN
-2.33%

AZN
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates

Compugen (CGEN) delivered earnings and revenue surprises of -200% and 91.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

CGEN
-2.33%
Compugen: Q4 Earnings Snapshot

HOLON, Israel (AP) — Compugen Ltd. (CGEN) on Tuesday reported a fourth-quarter loss of $6.1 million, after reporting a profit in the same period a year earlier. The Holon, Israel-based company said it had a loss of 7 cents per share. The results missed Wall Street expectations.

Associated Press Finance 2 months ago

CGEN
-2.33%
/C O R R E C T I O N -- Compugen Ltd./

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2024 and provided a corporate update.

PR Newswire 2 months ago

CGEN
-2.33%
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, Miami Beach, Florida, on Tuesday, March 11, 2025 at 8:00 AM ET.

PR Newswire 2 months ago

CGEN
-2.33%
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced results generated in a joint research collaboration, combining Compugen's AI/ML powered predictive computational discovery platform, Unigen, with high throughput single cell sequencing on Ultima's UG 100 to uncover new insights on gene structure for immuno-oncology.

PR Newswire 2 months ago

CGEN
-2.33%
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open. Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET.

PR Newswire 2 months ago

CGEN
-2.33%
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference which will take place virtually on February 11, 2025 at 8am ET.

PR Newswire 3 months ago

CGEN
-2.33%
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead. Compugen is responsible for running the Phase 1 trial.

PR Newswire 3 months ago

CGEN
-2.33%
The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

Simply Wall St. 4 months ago

CGEN
-2.33%
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced Fc, clinical stage antibody targeting TIGIT, and additional TIGIT backup antibodies in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the

PR Newswire 5 months ago

CGEN
-2.33%
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Compugen (NASDAQ:CGEN) has had a rough three months with its share price down 19%. But if you pay close attention, you...

Simply Wall St. 5 months ago

CGEN
-2.33%
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...

Compugen Ltd (CGEN) showcases strong financial stability and strategic advancements in ovarian cancer treatments amidst competitive challenges.

GuruFocus.com 5 months ago

CGEN
-2.33%
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates

Compugen (CGEN) delivered earnings and revenue surprises of -83.33% and 3.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

CGEN
-2.33%
Compugen: Q3 Earnings Snapshot

HOLON, Israel (AP) — Compugen Ltd. (CGEN) on Tuesday reported net income of $1.3 million in its third quarter. The Holon, Israel-based company said it had net income of 1 cent per share. The drug developer posted revenue of $17.1 million in the period.

Associated Press Finance 5 months ago

CGEN
-2.33%
Compugen Reports Third Quarter 2024 Results

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.

PR Newswire 5 months ago

CGEN
-2.33%

Performance Overview

Return	CGEN	TA-125 (^TA125.TA)
YTD	-16.00%	+10.00%
1-Year	-37.31%	+32.02%
3-Year	-35.05%	+35.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Compugen Ltd. (CGEN)

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts

Calculating The Intrinsic Value Of Compugen Ltd. (NASDAQ:CGEN)

Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates

Compugen: Q4 Earnings Snapshot

/C O R R E C T I O N -- Compugen Ltd./

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...

Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates

Compugen: Q3 Earnings Snapshot

Compugen Reports Third Quarter 2024 Results

Performance Overview